AR073263A1 - Derivados de piridina y su uso en diagnostico de imagenes mediante pet - Google Patents

Derivados de piridina y su uso en diagnostico de imagenes mediante pet

Info

Publication number
AR073263A1
AR073263A1 ARP090102997A ARP090102997A AR073263A1 AR 073263 A1 AR073263 A1 AR 073263A1 AR P090102997 A ARP090102997 A AR P090102997A AR P090102997 A ARP090102997 A AR P090102997A AR 073263 A1 AR073263 A1 AR 073263A1
Authority
AR
Argentina
Prior art keywords
compounds
aryl
substituted aryl
group
compositions
Prior art date
Application number
ARP090102997A
Other languages
English (en)
Inventor
Tobias Heinrich
Andrea Thiele
Lutz Lehmann
Sonja Vollmer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR073263A1 publication Critical patent/AR073263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos adecuados para marcar o ya marcados con 18F, con métodos para preparar tales compuestos, con composiciones que comprenden dichos compuestos, con conjuntos de elementos que comprenden dichos compuestos o composiciones y con los usos de dichos compuestos, composiciones o conjuntos de elementos en terapias y para diagnostico por imágenes mediante tomografía de emision de positrones (PET). Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde: R1 y R2 se seleccionan en forma independiente e individual, en cada instancia, entre el grupo que consiste de (G3)arilo, (G3)arilo sustituido, (G3-alquil C1-8)arilo, (G3-alcoxi C1-8)arilo, (G3-alquinil C2-8)arilo, (G3-alquenil C2-8)arilo, (G3-alquil C1-8)arilo sustituido, (G3-alcoxi C1-8)arilo sustituido, (G3-alquinil C2-8)arilo sustituido y (G3-alquenil C2-8)arilo sustituido; G1, G2 y G3 se seleccionan en forma independiente e individual, en cada instancia, entre el grupo que consiste de hidrogeno y L, con la condicion de que los compuestos de formula (1) contienen exactamente un L; L se selecciona entre el grupo que consiste de R3, [18F] fluoro y [19F] fluoro; R3 es un grupo saliente; donde n es un entero entre 0 y 6; incluyendo todas las formas isoméricas de dicho compuesto, incluyendo pero sin limitarse a enantiomeros y diastereoisomeros así como también mezclas racémicas, y cualquier sal, éster, amida, complejo o prodroga aceptable farmacéuticamente del mismo.
ARP090102997A 2008-08-06 2009-08-05 Derivados de piridina y su uso en diagnostico de imagenes mediante pet AR073263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161903 2008-08-06

Publications (1)

Publication Number Publication Date
AR073263A1 true AR073263A1 (es) 2010-10-28

Family

ID=41198601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102997A AR073263A1 (es) 2008-08-06 2009-08-05 Derivados de piridina y su uso en diagnostico de imagenes mediante pet

Country Status (24)

Country Link
US (1) US20110200535A1 (es)
EP (1) EP2321279B1 (es)
JP (1) JP2011529929A (es)
KR (1) KR20110041559A (es)
CN (1) CN102112448B (es)
AR (1) AR073263A1 (es)
AU (1) AU2009278279B2 (es)
BR (1) BRPI0917099A2 (es)
CA (1) CA2733105A1 (es)
CL (1) CL2011000237A1 (es)
CO (1) CO6351715A2 (es)
CR (1) CR20110064A (es)
DO (1) DOP2011000046A (es)
EA (1) EA018650B1 (es)
EC (1) ECSP11010808A (es)
IL (1) IL210597A0 (es)
MX (1) MX2011001406A (es)
NZ (1) NZ590923A (es)
PE (1) PE20110226A1 (es)
SV (1) SV2011003830A (es)
TW (1) TW201010734A (es)
UY (1) UY32037A (es)
WO (2) WO2010015340A1 (es)
ZA (1) ZA201101700B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2474526A3 (en) 2006-12-26 2012-07-25 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0904715D0 (en) 2009-03-19 2009-05-06 Ge Healthcare Ltd Aryloxyanilide derivataives
WO2011110488A1 (en) * 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft A novel pet imaging agent of amyloid plaques and its precursor
BR122020018194B1 (pt) * 2010-05-11 2021-07-27 Lantheus Medical Imaging, Inc. Composições e métodos de síntese de agentes de imagiologia
PT2571503E (pt) 2010-05-14 2015-04-29 Dana Farber Cancer Inst Inc Composições e a sua utilização no tratamento de neoplasia, doença inflamatória e outros distúrbios
JP6022442B2 (ja) 2010-05-14 2016-11-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 男性用避妊組成物および使用方法
CN103154246B (zh) * 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
BR112014005286B1 (pt) 2011-09-09 2022-08-23 Lantheus Medical Imaging, Inc Compostos de um primeiro e um segundo agente de imageamento para determinar incompatibilidade de inervação e perfusão na parte do indivíduo
RU2016105108A (ru) 2013-07-25 2017-08-30 Дана-Фарбер Кэнсер Инститьют, Инк. Ингибиторы факторов транскрипции и их применение
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
MX2016011160A (es) 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
EP3212654B1 (en) 2014-10-27 2020-04-08 Tensha Therapeutics, Inc. Bromodomain inhibitors
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
JP2018526421A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド シアノチエノトリアゾロジアゼピンおよびこれらの使用
SG10202007099TA (en) 2015-09-11 2020-08-28 Dana Farber Cancer Inst Inc Acetamide thienotriazoldiazepines and uses thereof
EP3380100A4 (en) 2015-11-25 2019-10-02 Dana-Farber Cancer Institute, Inc. BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF
CN105541931B (zh) * 2016-01-07 2018-08-17 江西师范大学 一种氟代糖苷衍生物及其制备方法
EA202091323A1 (ru) * 2017-12-01 2020-10-09 Юсб Байофарма Срл Визуализирующие средства
CN111039853B (zh) * 2019-12-26 2023-02-14 安徽大学 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1137878C (zh) * 1997-08-04 2004-02-11 大正制药株式会社 芳氧基苯胺衍生物
JP2000001476A (ja) * 1998-06-15 2000-01-07 Taisho Pharmaceut Co Ltd アリールオキシ含窒素アリールアミン誘導体
US6870069B2 (en) * 2003-01-10 2005-03-22 National Institute Of Radiological Sciences Phenyloxyaniline derivatives
JP2004231647A (ja) * 2003-01-10 2004-08-19 Natl Inst Of Radiological Sciences フェニルオキシアニリン誘導体
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method
EP1909853B1 (en) * 2005-07-19 2015-03-18 Biosensors International Group, Ltd. Imaging protocols
US20080293969A1 (en) * 2005-11-22 2008-11-27 Ge Healthcare Limited 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors
DE102005055524B4 (de) * 2005-11-22 2013-02-07 BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers
GB0525949D0 (en) * 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
WO2007148088A2 (en) * 2006-06-21 2007-12-27 Ge Healthcare Limited Radiopharmaceutical products
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment

Also Published As

Publication number Publication date
WO2010015340A1 (en) 2010-02-11
JP2011529929A (ja) 2011-12-15
EA018650B1 (ru) 2013-09-30
MX2011001406A (es) 2011-03-21
CR20110064A (es) 2011-03-30
IL210597A0 (en) 2011-03-31
BRPI0917099A2 (pt) 2016-02-16
UY32037A (es) 2010-03-26
NZ590923A (en) 2012-12-21
EP2321279A1 (en) 2011-05-18
ZA201101700B (en) 2014-08-27
US20110200535A1 (en) 2011-08-18
KR20110041559A (ko) 2011-04-21
CN102112448A (zh) 2011-06-29
ECSP11010808A (es) 2011-03-31
EP2321279B1 (en) 2014-07-02
CA2733105A1 (en) 2010-02-11
WO2010015387A1 (en) 2010-02-11
DOP2011000046A (es) 2011-02-28
CN102112448B (zh) 2014-08-06
PE20110226A1 (es) 2011-04-01
CO6351715A2 (es) 2011-12-20
EA201100301A1 (ru) 2011-12-30
SV2011003830A (es) 2011-05-20
CL2011000237A1 (es) 2011-07-29
AU2009278279B2 (en) 2014-04-17
AU2009278279A1 (en) 2010-02-11
TW201010734A (en) 2010-03-16

Similar Documents

Publication Publication Date Title
AR073263A1 (es) Derivados de piridina y su uso en diagnostico de imagenes mediante pet
PE20141160A1 (es) Metodos para preparar analogos nucleotidicos antivirales
UY30112A1 (es) Nuevos benzotiazoles sustitidos por heteroarilo
GT201300207A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CO6761397A2 (es) Métodos para preparar glicoesfingolípidos y usos de los mismos
AR071054A1 (es) Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa.
NI201400023A (es) Derivados de pirrolopirimidina y purina
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
ECSP12011857A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
ECSP14013215A (es) Compuestos novedosos
PE20091723A1 (es) Derivados de acido l-glutamico marcado con [18 f] y l-glutamina marcada con [18f]
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
SG194761A1 (en) Radiolabeled amino acids for diagnostic imaging
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
AR057067A1 (es) Procedimiento para preparar sales de tiotropio, sales de tiotropio como tales y composiciones farmaceuticas de las mismas
ES2528370T3 (es) Derivados (3-metilpirrolidín-3-il)metil-piridinil éter y su uso como antagonistas del receptor NK-3
AR086803A1 (es) Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras
AR086865A1 (es) Metodos y composiciones para el tratamiento del cancer de cerebro
AR072772A1 (es) Procedimiento de preparacion de combretastatina y uso del mismo
SG194759A1 (en) Novel precursors of glutamate derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal